Open-label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Elinzanetant in Participants With Impaired Renal Function in Comparison to Matched Controls With Normal Renal Function
Latest Information Update: 01 Nov 2022
At a glance
- Drugs Elinzanetant (Primary)
- Indications Sex hormone disorders; Vasomotor symptoms
- Focus Pharmacokinetics
- Sponsors Bayer
- 26 Oct 2022 Status changed from recruiting to completed.
- 16 Sep 2022 Planned End Date changed from 30 Aug 2022 to 30 Nov 2022.
- 16 Sep 2022 Planned primary completion date changed from 30 Aug 2022 to 30 Nov 2022.